The articles listed on this page are from a variety of sources. 
1. The staff of DBS-STN often attends conferences or educational opportunities both nationally and internationally, and a brief understandable write-up of the information presented at the event will be provided for our readers to review. 
2. DBS-STN staff also identifies or writes various articles related to topics that are thought to be of interest for the reader of www.DBS-STN.org. 

Browse by Topic:
Search:

Adamas Pharma Announces Submission of ADS-5102 NDA to US FDA as Dyskinesia Treatment in PD Patients


(October 31, 2016) - Adamas Pharmaceuticals, Inc announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for ADS-5102 (amantadine hydrochloride) extended-release capsules, the company’s proprietary lead product candidate, for the potential treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease. Read more



Article Archive

back